| abstract |
Compounds of structure (I) n nand pharmaceutically acceptable acid addition salts nthereof are described in which, n is 0 to 5; and X¹ to nX⁵ are any accessible combination of hydrogen, halogen, nC₁₋₆alkyl, C₁₋₆alkoxy, cyano, nitro, SONH₂, SO₂CH₃, nSO₂CH₂F, SO₂CHF₂, SO₂CF₃, CF₃, CHO, OH, CH₂OH, nCO₂H, CO₂C p H 2p+1 wherein p is 1 to 4. n These compounds are dopamine-β-hydroxylase inhibitors. nPharmaceutical compositions are described as are methods nof use. Processes for the preparation of these compounds nare described. |